NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

In response to the news on in-licensing deal by bioSeedin, Dr. Pawel Kalinski said the following:

Years of NCI-, NYSTAR- and Roswell Alliance Foundation-supported research and the last 2 years of negotiations allowed us to reach this milestone.

My thanks to all Lab Members involved and to the Technology Management - , Translational Immuno-Oncology - , Scientific Program Management - and Legal Teams for getting us to this point!

I look forward to working with colleagues at Northwest Bio, University of Pittsburgh and other members of Translational Research Consortium of Cancer Centers (TRCCC) and our partners at Moffitt and Emory, moving these newest platforms of DC and T cell therapies to patients.

I believe the following could be one of the trials which Roswell Park is running in collaboration with Moffitt.

Dendritic Cell Vaccines Against Her2/?Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
https://clinicaltrials.gov/study/NCT04348747


One thing I feel unusual about this trial is that over two years ago in April 2022 the collaborator was changed from NCI into the Department of Defense with new funding of $6,420,739.00 to Roswell Park and $8,318,389.00 to Moffitt. The funding came from Congressionally Directed Medial Research Programs on BCRP. Did LP say that the discussions and negotiation with Roswell were started over 2 years ago?

BETHESDA, MD, June 17, 2024 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that on June 12, 2024 it entered into an exclusive license from Roswell Park Comprehensive Cancer Center for a portfolio of dendritic cell technologies and intellectual property (IP). The technologies are already in Phase 2 clinical trials, and the Company plans to collaborate with the lead scientist-clinician, Dr. Pawel Kalinski, on the further development of the technologies. The license is the culmination of more than 2 years of discussions and negotiations.

https://cdmrp.health.mil/search.aspx?LOG_NO=BC180510

https://cdmrp.health.mil/bcrp/pbks/bcrp_programsummarysheet2023.pdf
https://cdmrp.health.mil/bcrp/default

One interesting part about Congressionally Directed Medial Research Programs is that for nearly each type of cancer listed there is always information about News & Highlights, Vision and Mission. But there is one exception which is GBM. When it comes to the description on News & Highlights, Vision and Mission, there is nothing about GBM. But the program does have $10m funding available. Waybackmachine didn't see GBM was added on March 23, 2024. But it did catch that GBM was added on May 26, 2024. I suspect Congressionally Directed Medial Research Programs are waiting for some latest input before presenting their vision and mission on GBM. I even think they are waiting for the same thing that the NWBO longs are excited about.

Now check when the webpage on Glioblastoma was added.
https://web.archive.org/web/20240315000000*/https://cdmrp.health.mil/researchprograms

March 23, 2024
https://web.archive.org/web/20240323223839/https://cdmrp.health.mil/researchprograms

May 26, 2024
https://web.archive.org/web/20240526195840/https://cdmrp.health.mil/researchprograms

Glioblastoma
https://cdmrp.health.mil/gbmrp/default

Breast Cancer
https://cdmrp.health.mil/bcrp/default

Kidney Cancer
https://cdmrp.health.mil/kcrp/default

Lung Cancer
https://cdmrp.health.mil/lcrp/default

Melanoma
https://cdmrp.health.mil/mrp/default

Ovarian Cancer
https://cdmrp.health.mil/ocrp/default

Pancreatic Cancer
https://cdmrp.health.mil/pcarp/default

Prostate Cancer
https://cdmrp.health.mil/pcrp/default

Rare Cancers
https://cdmrp.health.mil/rcrp/default